Trial
NCT03620149
Reduced Dose-density of Denosumab for Unresectable GCTB
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Amgen
Condition
Bone Giant Cell Tumor
Intervention
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Why stopped
Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-06